| Literature DB >> 30590924 |
Wenhan Zhang1, Shufeng Liu2, Rayelle I Maiga, Jerry Pelletier, Lauren E Brown1, Tony T Wang2, John A Porco1.
Abstract
As a unique rocaglate (flavagline) natural product, aglaroxin C displays intriguing biological activity by inhibiting hepatitis C viral entry. To further elucidate structure-activity relationships and diversify the pyrimidinone scaffold, we report a concise synthesis of aglaroxin C utilizing a highly regioselective pyrimidinone condensation. We have prepared more than 40 aglaroxin C analogues utilizing various amidine condensation partners. Through biological evaluation of analogues, we have discovered two lead compounds, CMLD012043 and CMLD012044, which show preferential bias for the inhibition of hepatitis C viral entry vs translation inhibition. Overall, the study demonstrates the power of chemical synthesis to produce natural product variants with both target inhibition bias and improved therapeutic indexes.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30590924 PMCID: PMC6583776 DOI: 10.1021/jacs.8b11477
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419